ENDRA Life Sciences (NDRA) EBITDA Margin (2016 - 2018)

ENDRA Life Sciences (NDRA) has reported EBITDA Margin for 3 consecutive years, with 45960.77% the latest figure, recorded in Q1 2018.

• In Q1 2018, EBITDA Margin changed N/A year-over-year to 45960.77%; the TTM figure through Dec 2018 stood at 146080.47% (down 14476512.0% YoY), while the FY2018 annual figure was 146080.47%, down 14476483.0% from the prior year.
• EBITDA Margin fell to 45960.77% in Q1 2018 per NDRA's latest filing, from 33526.58% in the prior quarter.
• Across five years, EBITDA Margin topped out at 61.85% in Q4 2016 and bottomed at 45960.77% in Q1 2018.
• Historically, EBITDA Margin has averaged 16339.19% across 3 years, with a median of 1829.36% in 2017.
• On a YoY basis, EBITDA Margin climbed as much as 3346474 bps in 2017 and fell as far as 3346474 bps in 2017.
• ENDRA Life Sciences' EBITDA Margin stood at 61.85% in 2016, then tumbled by 54107 bps to 33526.58% in 2017, then sank by 37 bps to 45960.77% in 2018.
• Business Quant data shows NDRA's EBITDA Margin at 45960.77% in Q1 2018, 33526.58% in Q4 2017, and 317.4% in Q3 2017.